Serum adenosine deaminase in patients with rheumatoid arthritis treated with methotrexate
Journal of Research in Pharmacy Practice · 2012
DOI: 10.4103/2279-042x.108374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Research in Pharmacy Practice, 2012. Verfasst von Mansour Salesi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVE: Recently, adenosine deaminase (ADA) is introduced as helpful marker in diagnosis, prognosis, and monitoring of treatment in rheumatoid arthritis (RA). The aim of this study was to determine the efficacy of the serum ADA in diagnosis, prognosis, and monitoring of treatment with methotrexate (MTX) in RA. METHODS: This was a self-controlled clinical trial conducted in university hospitals of Isfahan, Iran. The serum level of ADA, erythrocyte sedimentation rate (ESR), and rheumatoid factor (RF) were measured for 70 patients with active RA (Disease Activity Score-28 [DAS28] > 3/2). After three months of MTX treatment and disease remission (DAS28 < 2.6) these markers were measured again. ANCOVA multiregression and paired t-test were used to compare and evaluate the mean level and correlation of ADA, ESR, IgM-RF, and DAS before and after RA remission. FINDINGS: The mean value for ADA activity was significantly higher than the normal one compared with other studies. Significant decreases were seen in values of ADA, ESR, RF, visual analogue scale (VAS), and DAS after remission. Also, the correlation coefficient between the values of ADA with ESR and DAS were statistically significant in baseline. Moreover, the statistically significant correlation between ADA and ESR, VAS, and DAS were seen after remission. No correlation was found in the case of the dosage of MTX with the value of ADA. CONCLUSION: It was concluded that ADA may be considered useful as a marker in diagnosis, prognosis, and monitoring of treatment with Methotrexate in RA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Community and Preventive Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
- Skin Disease and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran ; Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Zitieren
APA
Salesi, M., Ghazvini, R. A., Farajzadegan, Z., Karimifar, M., Karimzadeh, H., Masoumi, M., & Ebrahimi, B. (2012). Serum adenosine deaminase in patients with rheumatoid arthritis treated with methotrexate. Journal of Research in Pharmacy Practice. https://doi.org/10.4103/2279-042x.108374
Vancouver
Salesi M, Ghazvini RA, Farajzadegan Z, Karimifar M, Karimzadeh H, Masoumi M, et al. Serum adenosine deaminase in patients with rheumatoid arthritis treated with methotrexate. Journal of Research in Pharmacy Practice. 2012. doi:10.4103/2279-042x.108374
BibTeX
@article{Salesi2012,
author = {Salesi, Mansour and Ghazvini, Rozita Aghaye and Farajzadegan, Ziba and Karimifar, Mansoor and Karimzadeh, Hadi and Masoumi, Maryam and Ebrahimi, Bahareh},
title = {Serum adenosine deaminase in patients with rheumatoid arthritis treated with methotrexate},
journal = {Journal of Research in Pharmacy Practice},
year = {2012},
doi = {10.4103/2279-042x.108374}
}
EUVIMED